TY - JOUR
T1 - Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium–glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus
T2 - Results from the CANTABILE study
AU - Son, Cheol
AU - Makino, Hisashi
AU - Kasahara, Masato
AU - Tanaka, Tomohiro
AU - Nishimura, Kunihiro
AU - Taneda, S.
AU - Nishimura, Takeshi
AU - Kasama, Shu
AU - Ogawa, Yoshihiro
AU - Miyamoto, Yoshihiro
AU - Hosoda, Kiminori
N1 - Funding Information:
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [CS received grants and personal fees from MSD, grants and personal fees, from Mitsubishi Tanabe Pharma Corporation, grants from Sanofi K.K., grants from Eli Lilly Japan K.K., grants from Novartis Pharma K.K., grants and personal fees from Takeda Pharmaceutical, personal fees from Taisho Toyama Pharmaceutical Co, personal fees from Fujifilm Pharma, and personal fees from Sumitomo Dainippon Pharma. MK received compensation as an advisor of the medical consulting firm Reason Why, Inc.; payments for lectures from Fuji Yakuhin, Pfizer, Daiichi Sankyo Co., Teijin, Fuji Film, Baxter, and Otsuka Pharmaceutical; and grants from Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., and Fuji Yakuhin. TT has stocks in Sumitomo Dainippon Pharma Co., Astellas Pharma Inc.; received payment for lectures from Taisho Toyama Pharmaceutical Co., Daiichi Sankyo Co., Mitsubishi Tanabe Pharma Corporation, AstraZeneca, EA Pharma Co., Kissei Pharmaceutical Co., Novartis Pharma, Takeda Pharmaceutical Co., Boehringer Ingelheim Japan, Kowa Pharmaceutical Co., MSD K.K., Astellas Pharma Inc., Ono Pharmaceutical Co., Amgen Astellas BioPharma K.K., Medtronic company, Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho, Co., Eli Lilly Japan K.K., the Japanese Society of Internal Medicine, Covidien Japan K.K., MMS Communications K.K. and Aichi Prefecture Insurance Medical Association; received honoraria for manuscript from Taisho Toyama Pharmaceutical Co., Nippon Rinsho Sha Co., Yodosha Co., Hokuryukan & NEW SCIENCE Co., SHINDAN TO CHIRYO SHA, Inc., and Kyoto University Press; and received grants from Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Kamitsure Laboratory Co., Smoking Research Foundation, Japan Society for the Promotion of Science, Kowa Pharmaceutical Co., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co., Novo Nordisk Pharma, Taisho Toyama Pharmaceutical Co., Novartis Pharma, and Sanofi K.K. KN received grants from Philips Japan Co., Terumo Co., and Daiichi Sankyo Co. ST received payment for lectures from Novo Nordisk Pharma and Takeda Pharmaceutical. SK received grants from Mitsubishi Tanabe Pharma Corporation. YO received grants and personal fees from Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., and Astellas Pharma Inc., grants from AstraZeneca, Kyowa Hakko Kirin, Taisho Pharmaceutical, Mochida Pharmaceutical, Cosmic Co., Miyarisan Pharmaceutical, Kissei Pharmaceutical, Kowa Pharmaceutical, Roche DC Japan, Boehringer Ingelheim Japan, Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho, Co., Sumitomo Dainippon Pharma, Sanofi K.K., Pfizer, Takeda Pharmaceutical. K.H. received grants, personal fees, and non-financial support from Mitsubishi Tanabe Pharma Co., personal fees from MSD, Sanofi, Eli Lilly, Novartis, Takeda, Astellas, Daiichi Sankyo, Amgen, Novo Nordisk Pharma, Kyowa Hakko Kirin, Ono, Sumitomo Dainippon, AstraZeneca, Taisho Pharma, Boehringer Ingelheim, and OMRON HEALTHCARE; grants from MSD, Sanofi, Eli Lilly, and Takeda. TN and YM declare no competing interests.].
Funding Information:
This work was supported by Mitsubishi Tanabe Pharma Corporation.
Publisher Copyright:
© 2021 The Authors
PY - 2021/10
Y1 - 2021/10
N2 - Aims: The aim of this study was to compare the effectiveness of teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, at reducing a composite outcome of three metabolic risk factors (obesity, hypertension, and dyslipidemia) in Japanese patients with type 2 diabetes mellitus (T2DM) and metabolic risks. Methods: In this prospective, multicenter, open-label, randomized, parallel-group comparison study, 162 patients with T2DM and one or more metabolic risk factors were randomized into a teneligliptin or canagliflozin group and treated for 24 weeks. The primary endpoint was the composite percentage of subjects who experienced an improvement in at least one metabolic risk after 24 weeks of treatment. Results: The primary endpoint was achieved significantly by more patients in the canagliflozin group than in the teneligliptin group (62.2% vs. 31.3%, p = 0.0004). A ≥ 3% body weight loss was also achieved by significantly more participants in the canagliflozin group than in the teneligliptin group (55.9% vs. 10.5%, p < 0.0001). Conclusions: This study showed canagliflozin to be more effective at reducing metabolic risks than teneligliptin. In Japanese patients with T2DM and metabolic risk factors, SGLT2 inhibitors may be superior to DPP-4 inhibitors at controlling multiple metabolic risk.
AB - Aims: The aim of this study was to compare the effectiveness of teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, at reducing a composite outcome of three metabolic risk factors (obesity, hypertension, and dyslipidemia) in Japanese patients with type 2 diabetes mellitus (T2DM) and metabolic risks. Methods: In this prospective, multicenter, open-label, randomized, parallel-group comparison study, 162 patients with T2DM and one or more metabolic risk factors were randomized into a teneligliptin or canagliflozin group and treated for 24 weeks. The primary endpoint was the composite percentage of subjects who experienced an improvement in at least one metabolic risk after 24 weeks of treatment. Results: The primary endpoint was achieved significantly by more patients in the canagliflozin group than in the teneligliptin group (62.2% vs. 31.3%, p = 0.0004). A ≥ 3% body weight loss was also achieved by significantly more participants in the canagliflozin group than in the teneligliptin group (55.9% vs. 10.5%, p < 0.0001). Conclusions: This study showed canagliflozin to be more effective at reducing metabolic risks than teneligliptin. In Japanese patients with T2DM and metabolic risk factors, SGLT2 inhibitors may be superior to DPP-4 inhibitors at controlling multiple metabolic risk.
UR - http://www.scopus.com/inward/record.url?scp=85116024043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116024043&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2021.109037
DO - 10.1016/j.diabres.2021.109037
M3 - Article
C2 - 34481910
AN - SCOPUS:85116024043
VL - 180
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
M1 - 109037
ER -